Sakai Chemical Industry Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018; Announces Dividend for the Six Months Ended September 30, 2017, Payable on December 5, 2017; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2018
November 06, 2017
Share
Sakai Chemical Industry Co., Ltd. announced consolidated earnings results for the six months ended September 30, 2017. For the period, the consolidated company reported net sales of ¥42,931 million, operating profit of ¥2,322 million, ordinary profit of ¥2,210 million, net profit attributable to owners of the parent of the company of ¥1,205 million or income per share of ¥66.84 compared to net sales of ¥40,515 million, operating income of ¥1,868 million, ordinary profit of ¥1,342 million, profit attributable to owners of the parent of the company of ¥654 million or net income per basic share of ¥34.75 for the same period last year. Profit before income taxes was ¥1,931 million against ¥1,185 million a year ago.
The company announced dividend of ¥4.00 per share for the six months ended September 30, 2017 against ¥4.00 per share a year ago. The company will pay dividend on December 5, 2017.
The company expects to pay year end dividend of ¥20.00 per share for the fiscal year ending March 31, 2018.
For the year ending March 31, 2018, the consolidated company expects net sales of ¥86,000 million, operating profit of ¥3,900 million, ordinary profit of ¥3,300 million, profit attributable to owners of the parent of the company of ¥1,700 million or net income per share of ¥92.85.
SAKAI CHEMICAL INDUSTRY CO., LTD. is a Japan-based company principally manufactures and sells chemical industry products. The Company operates in two business segments. Chemical segment is involved in the manufacture and sale of chemical products. Main products include titanium products, resin additives, barium products, catalyst products, electronic materials, zinc products, functional materials, and other chemicals such as organophosphorus compounds, organic sulfur compounds, as well as water treatment agents, among others. Medical segment is involved in the manufacture and sale of pharmaceuticals and quasi drugs. Main products include barium X-ray contrast media, medical drugs for peptic ulcer & reflux esophagitis, general drugs such as cold and gastrointestinal drugs, functional foods, as well as other products such as medical devices, among others.
Sakai Chemical Industry Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018; Announces Dividend for the Six Months Ended September 30, 2017, Payable on December 5, 2017; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2018